Glucose-6-phosphate dehydrogenase: A biomarker and potential therapeutic target for cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 2, 2014, Pages 280-289

  Zhang, Chunhua ^a,b   Zhang, Zheng ^a   Zhu, Yuechun ^a   Qin, Suofu ^c  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b Yunnan Maternal and Child Health Hospital   (China)

^c ALLERGAN INC   (United States)

Author keywords

Cancer metabolisms; Glucose 6 phosphate dehydrogenase; NADPH; Oxidative stress; Reactive oxygen species; Therapeutic target

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; COMBINED MODALITY THERAPY; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOLYSIS; HUMANS; LIPOGENESIS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REACTIVE OXYGEN SPECIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84893484071     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660337     Document Type: Review

References (112)

1. Fearon, E. R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61, 759-767.
2. Ferreira, L. M. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol., 2010, 89, 372-380.
3. Aksoy, Y.; Ogus, I. H.; Oauzer, N. Purification and some properties of human placental glucose-6-phosphate dehydrogenase. Protein Exp. Purif., 2001, 21, 286-292.
4. Alving, A. S.; Carson, P. E.; Flanagan, C. L.; Ickes, C. E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science, 1956, 124, 484-485.
5. Martini, G.; Toniolo, D.; Vulliamy, T.; Luzzatto, L.; Dono, R.; Viglietto, G.; Paonessa, G.; D'Urso, M.; Persico, M. G. Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J., 1986, 5, 1849-1855.
6. Beutler, E. G6PD deficiency. Blood, 1994, 84, 3613-3636.
7. Vulliamy, T. J.; Kaeda, J. S.; Ait-Chafa, D.; Mangerini, R.; Roper, D.; Barbot, J.; Mehta, A. B.; Athanassiou-Metaxa, M.; Luzzatto, L.; Mason, P. J. Clinical and haematological consequences of recurrent G6PD mutations and a single new mutation causing chronic nonspherocytic haemolytic anaemia. Br. J. Haematol., 1998, 101, 670-675.
8. Beutler, E. Study of glucose-6-phosphate dehydrogenase: History and molecular biology. Am. J. Hematol., 1993, 42, 53-58.
9. Au, S. W.; Gover, S.; Lam, V. M.; Adams, M. J. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure, 2000, 8, 293-303.
10. Eggleston, L. V.; Krebs, H. A. Regulation of the pentose phosphate cycle. Biochem. J., 1974, 138, 425-435.
11. Kuo, W. Y.; Tang, T. K. Effects of G6PD overexpression in NIH3T3 cells treated with tert-butyl hydroperoxide or paraquat. Free Radic. Biol. Med., 1998, 24, 1130-1138.
12. Beutler, E. Drug-induced hemolytic anemia. Pharmacol. Rev., 1969, 21, 73-103.
13. Yang, Y.; Zhu, Y.; Li, D.; Li, Z.; Lu, H.; Wu, J.; Tang, J.; Tong, S. Characterization of glucose-6-phosphate dehydrogenase deficiency and identification of a novel haplotype 487G>A/IVS5-612(G>C) in the Achang population of Southwestern China. Sci. China C. Life Sci., 2007, 50, 479-485.
14. Lu, H. R.; Tang, Q. L.; Wang, X.; Li, H. J.; Li, D. Y.; Yang, Y. F.; Tong, S. F.; Zhang, C. H.; Zhu, Y. C. Enzyme kinetics and molecular modeling studies of G6PD(Mahidol) associated with acute hemolytic anemia. Indian J. Biochem. Biophys., 2011, 48, 316-324.
15. Kuo, W.; Lin, J.; Tang, T. K. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int. J. Cancer, 2000, 85, 857-864.
16. Rais, B.; Comin, B.; Puigjaner, J.; Brandes, J. L.; Creppy, E.; Saboureau, D.; Ennamany, R.; Lee, W. N.; Boros, L. G.; Cascante, M. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett., 1999, 456, 113-118.
17. Ramao, A.; Gimenez, M.; Laure, H. J.; Izumi, C.; Vida, R. C.; Oba-Shinjo, S.; Marie, S. K.; Rosa, J. C. Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines. Proteome Sci., 2012, 10, 53.
18. Baba, M.; Yamamoto, R.; Iishi, H.; Tatsuta, M.; Wada, A. Role of glucose-6-phosphate dehydrogenase on enhanced proliferation of pre-neoplastic and neoplastic cells in rat liver induced by Nnitrosomorpholine. Int. J. Cancer, 1989, 43, 892-895.
19. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899.
20. Wellen, K. E.; Hatzivassiliou, G.; Sachdeva, U. M.; Bui, T. V.; Cross, J. R.; Thompson, C. B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science, 2009, 324, 1076-1080.
21. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
22. DeBerardinis, R. J.; Lum, J. J.; Hatzivassiliou, G.; Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 2008, 7, 11-20.
23. Liu, X.; Wang, X.; Zhang, J.; Lam, E. K.; Shin, V. Y.; Cheng, A. S.; Yu, J.; Chan, F. K.; Sung, J. J.; Jin, H. C. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene, 2010, 29, 442-450.
24. Pastorino, J. G.; Hoek, J. B. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr. Med. Chem., 2003, 10, 1535-1551.
25. Yamada, K.; Noguchi, T. Regulation of pyruvate kinase M gene expression. Biochem. Biophys. Res. Commun., 1999, 256, 257-262.
26. Menendez, J. A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer, 2007, 7, 763-777.
27. Leschelle, X.; Delpal, S.; Goubern, M.; Blottiere, H. M.; Blachier, F. Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur. J. Biochem., 2000, 267, 6435-6442.
28. Jeon, S. M.; Chandel, N. S.; Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 2012, 485, 661-665.
29. Bandyopadhyay, S.; Zhan, R.; Wang, Y.; Pai, S. K.; Hirota, S.; Hosobe, S.; Takano, Y.; Saito, K.; Furuta, E.; Iiizumi, M.; Mohinta, S.; Watabe, M.; Chalfant, C.; Watabe, K. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res., 2006, 66, 5934-5940.
30. Huang, W. C.; Li, X.; Liu, J.; Lin, J.; Chung, L. W. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res., 2012, 10, 133-142.
31. Hashimoto, Y.; Shiotani, T.; Eble, J. N.; Glover, J. L.; Weber, G. Increased thymidylate synthase (EC 2. 1. 1. 45) activity in normal and neoplastic proliferation. Cancer Biochem. Biophys., 1988, 10, 1-10.
32. Kawasaki, G.; Yoshitomi, I.; Yanamoto, S.; Yamada, S.; Mizuno, A.; Umeda, M. Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82. Anticancer Res., 2011, 31, 3521-3526.
33. Hashemy, S. I.; Ungerstedt, J. S.; Zahedi Avval, F.; Holmgren, A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006, 281, 10691-10697.
34. Kawakami, K.; Ruszkiewicz, A.; Bennett, G.; Moore, J.; Watanabe, G.; Iacopetta, B. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin. Cancer Res., 2003, 9, 5860-5865.
35. Gandin, V.; Fernandes, A. P.; Rigobello, M. P.; Dani, B.; Sorrentino, F.; Tisato, F.; Bjornstedt, M.; Bindoli, A.; Sturaro, A.; Rella, R.; Marzano, C. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol., 2010, 79, 90-101.
36. Szatrowski, T. P.; Nathan, C. F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res., 1991, 51, 794-798.
37. Halliwell, B. Oxidative stress and cancer: have we moved forward? Biochem. J., 2007, 401, 1-11.
38. Sablina, A. A.; Budanov, A. V.; Ilyinskaya, G. V.; Agapova, L. S.; Kravchenko, J. E.; Chumakov, P. M. The antioxidant function of the p53 tumor suppressor. Nat. Med., 2005, 11, 1306-1313.
39. Elchuri, S.; Oberley, T. D.; Qi, W.; Eisenstein, R. S.; Roberts, J. L.; Van Remmen, H.; Epstein, C. J.; Huang, T. T. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene, 2005, 24, 367-380.
40. Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; Nakada, K.; Honma, Y.; Hayashi, J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 2008, 320, 661-664.
41. Wu, W. S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev., 2006, 25, 695-705.
42. Majmundar, A. J.; Wong, W. J.; Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell, 2010, 40, 294-309.
43. Grivennikov, S. I.; Greten, F. R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
44. Kamata, H.; Honda, S.; Maeda, S.; Chang, L.; Hirata, H.; Karin, M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell, 2005, 120, 649-661.
45. Fridovich, I. The biology of oxygen radicals. Science, 1978, 201, 875-880.
46. Hamanaka, R. B.; Chandel, N. S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci., 2010, 35, 505-513.
47. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J., 2009, 417, 1-13.
48. Brandon, M.; Baldi, P.; Wallace, D. C. Mitochondrial mutations in cancer. Oncogene, 2006, 25, 4647-4662.
49. Bell, E. L.; Klimova, T. A.; Eisenbart, J.; Moraes, C. T.; Murphy, M. P.; Budinger, G. R.; Chandel, N. S. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell. Biol., 2007, 177, 1029-1036.
50. Laursen, T.; Jensen, K.; Moller, B. L. Conformational changes of the NADPH-dependent cytochrome P450 reductase in the course of electron transfer to cytochromes P450. Biochim. Biophys. Acta, 2011, 1814, 132-138.
51. Arbiser, J. L.; Petros, J.; Klafter, R.; Govindajaran, B.; McLaughlin, E. R.; Brown, L. F.; Cohen, C.; Moses, M.; Kilroy, S.; Arnold, R. S.; Lambeth, J. D. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. USA, 2002, 99, 715-720.
52. Marletta, M. A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell, 1994, 78, 927-930.
53. Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol., 2004, 4, 181-189.
54. Babior, B. M. The respiratory burst oxidase. Curr. Opin. Hematol., 1995, 2, 55-60.
55. Griendling, K. K.; Sorescu, D.; Ushio-Fukai, M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res., 2000, 86, 494-501.
56. Ufer, C.; Wang, C. C.; Borchert, A.; Heydeck, D.; Kuhn, H. Redox control in mammalian embryo development. Antioxid. Redox Signal., 2010, 13, 833-875.
57. Longo, L.; Vanegas, O. C.; Patel, M.; Rosti, V.; Li, H.; Waka, J.; Merghoub, T.; Pandolfi, P. P.; Notaro, R.; Manova, K.; Luzzatto, L. Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO J., 2002, 21, 4229-4239.
58. Matsui, R.; Xu, S.; Maitland, K. A.; Mastroianni, R.; Leopold, J. A.; Handy, D. E.; Loscalzo, J.; Cohen, R. A. Glucose-6-phosphate dehydrogenase deficiency decreases vascular superoxide and atherosclerotic lesions in apolipoprotein E(-/-) mice. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 910-916.
59. Zuurbier, C. J.; Eerbeek, O.; Goedhart, P. T.; Struys, E. A.; Verhoeven, N. M.; Jakobs, C.; Ince, C. Inhibition of the pentose phosphate pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart. Cardiovasc. Res., 2004, 62, 145-153.
60. Amaral, A. I.; Teixeira, A. P.; Martens, S.; Bernal, V.; Sousa, M. F.; Alves, P. M. Metabolic alterations induced by ischemia in primary cultures of astrocytes: merging 13C NMR spectroscopy and metabolic flux analysis. J. Neurochem., 2010, 113, 735-748.
61. Jonas, S. K.; Benedetto, C.; Flatman, A.; Hammond, R. H.; Micheletti, L.; Riley, C.; Riley, P. A.; Spargo, D. J.; Zonca, M.; Slater, T. F. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspensions and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br. J. Cancer., 1992, 66, 185-191.
62. Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene, 2006, 25, 4633-4646.
63. Bensaad, K.; Tsuruta, A.; Selak, M. A.; Vidal, M. N.; Nakano, K.; Bartrons, R.; Gottlieb, E.; Vousden, K. H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006, 126, 107-120.
64. Gao, L.; Mejias, R.; Echevarria, M.; Lopez-Barneo, J. Induction of the glucose-6-phosphate dehydrogenase gene expression by chronic hypoxia in PC12 cells. FEBS Lett., 2004, 569, 256-260.
65. Leopold, J. A.; Walker, J.; Scribner, A. W.; Voetsch, B.; Zhang, Y. Y.; Loscalzo, A. J.; Stanton, R. C.; Loscalzo, J. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J. Biol. Chem., 2003, 278, 32100-32106.
66. Tian, W. N.; Braunstein, L. D.; Pang, J.; Stuhlmeier, K. M.; Xi, Q. C.; Tian, X.; Stanton, R. C. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J. Biol. Chem., 1998, 273, 10609-10617.
67. Fico, A.; Paglialunga, F.; Cigliano, L.; Abrescia, P.; Verde, P.; Martini, G.; Iaccarino, I.; Filosa, S. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stressinduced apoptosis. Cell Death Differ., 2004, 11, 823-831.
68. Jiang, P.; Du, W.; Wang, X.; Mancuso, A.; Gao, X.; Wu, M.; Yang, X. P53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol., 2011, 13, 310-316.
69. Tian, W. N.; Braunstein, L. D.; Apse, K.; Pang, J.; Rose, M.; Tian, X.; Stanton, R. C. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am. J. Physiol., 1999, 276, C1121-1131.
70. Li, D.; Zhu, Y.; Tang, Q.; Lu, H.; Li, H.; Yang, Y.; Li, Z.; Tong, S. A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. Cancer Biother. Radiopharm., 2009, 24, 81-90.
71. Cosentino, C.; Grieco, D.; Costanzo, V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J., 2011, 30, 546-555.
72. Efferth, T.; Fabry, U.; Osieka, R. DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenasedeficient patients (G6PD Aachen variant) after UV irradiation. J. Leukoc. Biol., 2001, 69, 340-342.
73. Pan, S.; World, C. J.; Kovacs, C. J.; Berk, B. C. Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 895-901.
74. Fukumura, D.; Gohongi, T.; Kadambi, A.; Izumi, Y.; Ang, J.; Yun, C. O.; Buerk, D. G.; Huang, P. L.; Jain, R. K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA, 2001, 98, 2604-2609.
75. Vizan, P.; Sanchez-Tena, S.; Alcarraz-Vizan, G.; Soler, M.; Messeguer, R.; Pujol, M. D.; Lee, W. N.; Cascante, M. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis, 2009, 30, 946-952.
76. Langbein, S.; Frederiks, W. M.; Zur Hausen, A.; Popa, J.; Lehmann, J.; Weiss, C.; Alken, P.; Coy, J. F. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int. J. Cancer, 2008, 122, 2422-2428.
77. Vegran, F.; Boidot, R.; Michiels, C.; Sonveaux, P.; Feron, O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res., 2011, 71, 2550-2560.
78. Kusmartsev, S.; Gabrilovich, D. I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol., 2003, 74, 186-196.
79. Talmadge, J. E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res., 2007, 13, 5243-5248.
80. Aurelius, J.; Thoren, F. B.; Akhiani, A. A.; Brune, M.; Palmqvist, L.; Hansson, M.; Hellstrand, K.; Martner, A. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. Blood, 2012, 119, 5832-5837.
81. Corzo, C. A.; Cotter, M. J.; Cheng, P.; Cheng, F.; Kusmartsev, S.; Sotomayor, E.; Padhya, T.; McCaffrey, T. V.; McCaffrey, J. C.; Gabrilovich, D. I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol., 2009, 182, 5693-5701.
82. Boudreau, H. E.; Casterline, B. W.; Rada, B.; Korzeniowska, A.; Leto, T. L. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic. Biol. Med., 2012, 53, 1489-1499.
83. Chang, J.; Jiang, Z.; Zhang, H.; Zhu, H.; Zhou, S. F.; Yu, X. NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. Int. J. Mol. Med., 2011, 28, 405-412.
84. Shim, H.; Dolde, C.; Lewis, B. C.; Wu, C. S.; Dang, G.; Jungmann, R. A.; Dalla-Favera, R.; Dang, C. V. C-Myc transactivation of LDHA: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA, 1997, 94, 6658-6663.
85. Maly, K.; Hochleitner, B.; Uberall, F.; Loferer, H.; Oberhuber, H.; Doppler, W.; Grunicke, H. Mechanism and biological significance of the Ha-ras-induced activation of the Na+/H(+)-antiporter. Adv. Enzyme Regul., 1990, 30, 63-74.
86. Gallagher, S. M.; Castorino, J. J.; Wang, D.; Philp, N. J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res., 2007, 67, 4182-4189.
87. Hu, L. H.; Yang, J. H.; Zhang, D. T.; Zhang, S.; Wang, L.; Cai, P. C.; Zheng, J. F.; Huang, J. S. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs, 2007, 18, 427-433.
88. Savina, A.; Jancic, C.; Hugues, S.; Guermonprez, P.; Vargas, P.; Moura, I. C.; Lennon-Dumenil, A. M.; Seabra, M. C.; Raposo, G.; Amigorena, S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell, 2006, 126, 205-218.
89. Van Noorden, C. J. A simple histochemical assay to detect cancer cells. Folia. Histochem. Cytobiol., 2000, 38, 99-102.
90. De Jong, J. S.; Frederiks, W. M.; Van Noorden, C. J. Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the detection of (pre)neoplasm in rat liver. J. Histochem. Cytochem., 2001, 49, 565-572.
91. Frederiks, W. M.; Vreeling-Sindelarova, H.; Van Noorden, C. J. Loss of peroxisomes causes oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity to detect cancer cells. J. Histochem. Cytochem., 2007, 55, 175-181.
92. Wang, J.; Yuan, W.; Chen, Z.; Wu, S.; Chen, J.; Ge, J.; Hou, F. Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. Tumour Biol., 2012, 33, 95-101.
93. Ratko, T. A.; Detrisac, C. J.; Mehta, R. G.; Kelloff, G. J.; Moon, R. C. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res., 1991, 51, 481-486.
94. Rao, K. V.; Johnson, W. D.; Bosland, M. C.; Lubet, R. A.; Steele, V. E.; Kelloff, G. J.; McCormick, D. L. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res., 1999, 59, 3084-3089.
95. Inano, H.; Ishii-Ohba, H.; Suzuki, K.; Yamanouchi, H.; Onoda, M.; Wakabayashi, K. Chemoprevention by dietary dehydroepiandrosterone against promotion/progression phase of radiationinduced mammary tumorigenesis in rats. J. Steroid Biochem. Mol. Biol., 1995, 54, 47-53.
96. Budihardjo, I. I.; Walker, D. L.; Svingen, P. A.; Buckwalter, C. A.; Desnoyers, S.; Eckdahl, S.; Shah, G. M.; Poirier, G. G.; Reid, J. M.; Ames, M. M.; Kaufmann, S. H. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin. Cancer Res., 1998, 4, 117-130.
97. Svec, F.; Porter, J. R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc. Soc. Exp. Biol. Med., 1998, 218, 174-191.
98. Mortola, J. F.; Yen, S. S. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J. Clin. Endocrinol. Metab., 1990, 71, 696-704.
99. Perkins, S. N.; Hursting, S. D.; Haines, D. C.; James, S. J.; Miller, B. J.; Phang, J. M. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis, 1997, 18, 989-994.
100. Schwartz, A. G.; Pashko, L. L. Suppression of 12-Otetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alphafluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett., 2001, 168, 7-14.
101. Hamilton, N. M.; Dawson, M.; Fairweather, E. E.; Hamilton, N. S.; Hitchin, J. R.; James, D. I.; Jones, S. D.; Jordan, A. M.; Lyons, A. J.; Small, H. F.; Thomson, G. J.; Waddell, I. D.; Ogilvie, D. J. Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. J. Med. Chem., 2012, 55, 4431-4445.
102. Shin, E. S.; Park, J.; Shin, J. M.; Cho, D.; Cho, S. Y.; Shin, D. W.; Ham, M.; Kim, J. B.; Lee, T. R. Catechin gallates are NADP+-competitive inhibitors of glucose-6-phosphate dehydrogenase and other enzymes that employ NADP+ as a coenzyme. Bioorg. Med. Chem., 2008, 16, 3580-3586.
103. Tandogan, B.; Kuruuzum-Uz, A.; Sengezer, C.; Guvenalp, Z.; Demirezer, L. O.; Ulusu, N. N. In vitro effects of rosmarinic acid on glutathione reductase and glucose 6-phosphate dehydrogenase. Pharm. Biol., 2011, 49, 587-594.
104. Preuss, J.; Richardson, A. D.; Pinkerton, A.; Hedrick, M.; Sergienko, E.; Rahlfs, S.; Becker, K.; Bode, L. Identification and characterization of novel human glucose-6-phosphate dehydrogenase inhibitors. J. Biomol. Screen., 2013, 18(3), 286-297.
105. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8, 579-591.
106. Friesen, C.; Kiess, Y.; Debatin, K. M. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ., 2004, 11 (Suppl 1), S73-85.
107. Gessner, T.; Vaughan, L. A.; Beehler, B. C.; Bartels, C. J.; Baker, R. M. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res., 1990, 50, 3921-3927.
108. Polimeni, M.; Voena, C.; Kopecka, J.; Riganti, C.; Pescarmona, G.; Bosia, A.; Ghigo, D. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem. J., 2011, 439, 141-149.
109. Tuttle, S.; Stamato, T.; Perez, M. L.; Biaglow, J. Glucose-6-phosphate dehydrogenase and the oxidative pentose phosphate cycle protect cells against apoptosis induced by low doses of ionizing radiation. Radiat. Res., 2000, 153, 781-787.
110. Sharma, P. K.; Bhardwaj, R.; Dwarakanath, B. S.; Varshney, R. Metabolic oxidative stress induced by a combination of 2-DG and 6-AN enhances radiation damage selectively in malignant cells via non-coordinated expression of antioxidant enzymes. Cancer Lett., 2010, 295, 154-166.
111. Ward, P. S.; Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell, 2012, 21, 297-308.
112. Stanton, R. C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life, 2012, 64, 362-369.